THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 92 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2014. The put-call ratio across all filers is 0.66 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $793,000 | -15.7% | 23,161 | -1.9% | 0.00% | -25.0% |
| Q2 2017 | $941,000 | +8.0% | 23,621 | -0.1% | 0.00% | 0.0% |
| Q1 2017 | $871,000 | +11.7% | 23,648 | -3.3% | 0.00% | +33.3% |
| Q4 2016 | $780,000 | -9.2% | 24,465 | +3.2% | 0.00% | -25.0% |
| Q3 2016 | $859,000 | +32.4% | 23,695 | -17.1% | 0.00% | +33.3% |
| Q2 2016 | $649,000 | +86.5% | 28,591 | +54.3% | 0.00% | +50.0% |
| Q1 2016 | $348,000 | +17.2% | 18,532 | +2.3% | 0.00% | +100.0% |
| Q4 2015 | $297,000 | +65.0% | 18,110 | +10.6% | 0.00% | 0.0% |
| Q3 2015 | $180,000 | -15.5% | 16,369 | 0.0% | 0.00% | 0.0% |
| Q2 2015 | $213,000 | -28.8% | 16,369 | -5.0% | 0.00% | 0.0% |
| Q1 2015 | $299,000 | +12.8% | 17,229 | -3.2% | 0.00% | 0.0% |
| Q4 2014 | $265,000 | -36.5% | 17,792 | -1.6% | 0.00% | -50.0% |
| Q3 2014 | $417,000 | -27.9% | 18,080 | -0.2% | 0.00% | 0.0% |
| Q2 2014 | $578,000 | – | 18,116 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Woodford Investment Management Ltd | 10,898,879 | $264,297,000 | 23.51% |
| Foundation Asset Management, LP | 399,537 | $9,689,000 | 3.59% |
| Cormorant Asset Management, LP | 1,300,000 | $31,525,000 | 2.35% |
| Baupost Group | 9,309,168 | $225,747,000 | 2.18% |
| Old West Investment Management, LLC | 109,320 | $2,651,000 | 1.53% |
| SENZAR ASSET MANAGEMENT, LLC | 187,856 | $4,555,000 | 1.44% |
| Chescapmanager LLC | 350,631 | $8,503,000 | 1.27% |
| Virtus ETF Advisers LLC | 32,989 | $800,000 | 0.69% |
| Rock Springs Capital Management LP | 652,600 | $15,826,000 | 0.68% |
| NJ State Employees Deferred Compensation Plan | 34,142 | $828,000 | 0.15% |